The FY23 Defense Appropriations Act provides funding for the Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
After the stunning success of mRNA vaccines during the COVID-19 pandemic, researchers and biotech companies are racing to prove the utility of the technology in an array of non-communicable diseases—including cancer, cystic fibrosis, and sickle cell disease.
